# Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

> **NCT03664804** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 95 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **OTHER:** No Study Drug was Administered in this Study

## Key facts

- **NCT ID:** NCT03664804
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-05
- **Primary completion:** 2021-05-07
- **Final completion:** 2022-05-07
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664804, "Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03664804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*